Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;85(Pt B):134-148.
doi: 10.1016/j.bpobgyn.2022.01.009. Epub 2022 Feb 2.

Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation

Yulia Koloda  1 , Vladislav Korsak  2 , Oleg Rozenson  3 , Margarita Anshina  4 , Karina Sagamonova  5 , Igor Baranov  6 , Sergey Yakovenko  7 , Thomas D'Hooghe  8 , Anna Ershova  9 , Monica Lispi  10
Affiliations
Free article

Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation

Yulia Koloda et al. Best Pract Res Clin Obstet Gynaecol. 2022 Dec.
Free article

Abstract

Two observational studies in the Russian Federation described patient demographics/clinical decision for treatment with recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for ovarian stimulation (OS) during assisted reproductive technology (ART) and outcomes, respectively. The first (prospective) study enrolled 500 patients. After post-hoc regrouping to assign patients to discrete groups, 378 (75.6%) met the local Russian label for an r-hFSH:r-hLH 2:1 combination, 105 (21%) were treated according to other physician preference, and 17 (3.4%) met only the ESHRE Bologna criteria for a poor ovarian response. The clinical pregnancy rate per cycle was 30.4%. A total of 158/175 (90.3%) women achieving clinical pregnancy in the prospective study participated in the second (retrospective) study. The live birth rate per cycle was 25.8%. No new safety concerns were reported. These results support the use of the r-hFSH:r-hLH 2:1 combination in patients with a poor/suboptimal response to OS for ART treatment in the Russian Federation.

Keywords: Assisted reproductive technology; Clinical practice; Real-world data; Suboptimal/poor ovarian response; r-hFSH; r-hLH.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest TDH and ML are employees of Merck Healthcare KGaA, Darmstadt, Germany. AE and OR are employees of Biopharma, LCC Merck, Moscow, Russian Federation, an affiliate of Merck KGaA. YK received speaker fees/honoraria/grants from MSD, Merck Healthcare KGaA, Darmstadt, Germany, Besins Healthcare, Gedeon Richter, Abbott, Bayer, and Sun Pharma. Margarita Anshina received speaker fees/honoraria/grants from MSD, Merck Healthcare KGaA, Darmstadt, Germany, Besins Healthcare, Gedeon Richter, Abbott, Bayer, and Sun Pharma. Vladislav Korsak received speaker fees/honoraria/grants from MSD, Merck Healthcare KGaA, Darmstadt, Germany, Besins Healthcare, Gedeon Richter, Abbott, Bayer, and Sun Pharma. Karina Sagamonova received speaker fees/honoraria/grants from MSD, Merck Healthcare KGaA, Darmstadt, Germany, Besins Healthcare, Gedeon Richter, Abbott, Bayer, and Sun Pharma. Igor Baranov received speaker fees/honoraria/grants from MSD and Besins Healthcare. SY reports no conflicts of interest.

MeSH terms

Substances

LinkOut - more resources